Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NKX3-1
REST API REST API
Homo sapiens
NKX3-1 is differentially expressed in 295 experiments: 153 organism parts: prostate, trachea, ... (151 more);, 204 disease states: normal, prostate carcinoma, ... (202 more);, 91 cell types 432 cell lines 41 compound treatments and 77 other conditions.
Synonyms BAPX2, NKX3A, NKX3.1
Orthologs Nkx3-1 (Rattus norvegicus)   NKX3-1 (Bos taurus)   Nkx3-1 (Mus musculus)   nkx3-1 (Danio rerio)   nkx3-1 (Xenopus laevis)   NKX3-1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term salivary gland development, positive regulation of cell division, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, negative regulation of cell proliferation, transcription, DNA-dependent, somitogenesis, transcription factor binding, sequence-specific DNA binding, positive regulation of mitotic cell cycle, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, heart development, negative regulation of epithelial cell proliferation, positive regulation of transcription, DNA-dependent, pharyngeal system development, negative regulation of epithelial cell proliferation involved in prostate gland development, estrogen receptor signaling pathway, negative regulation of insulin-like growth factor receptor signaling pathway, branching morphogenesis of a tube, branching involved in prostate gland morphogenesis, estrogen receptor binding, estrogen receptor activity, epithelial cell proliferation involved in salivary gland morphogenesis, sequence-specific DNA binding transcription factor activity, transcription regulatory region sequence-specific DNA binding, negative regulation of estrogen receptor binding
InterPro Term Homeobox, Homeobox_eu
UniProt Accession Q99801
Search EB-eye ENSG00000167034
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-7224, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (46 experiments)

Factor Value U/D Experiments
LNCaP
3
E-GEOD-14464, E-GEOD-14990, E-GEOD-762
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
PC3
3
E-GEOD-14464, E-GEOD-5258, E-MEXP-2034
AGS
2
E-MTAB-37, E-GEOD-15460
HepG2
2
E-GEOD-21154, E-MTAB-37
MCF-10A
2
E-TABM-420, E-GEOD-14990
426 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (45 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-8286
monocyte
1
2
E-GEOD-11755, E-GEOD-22373, E-GEOD-8286
primary fibroblast
1
E-MEXP-66
wild_type
1
E-GEOD-20193
epidermoid
1
E-GEOD-19397
LCC
1
E-GEOD-19188
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-2280, E-MTAB-62, E-GEOD-5370, ... (56 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
5
E-MTAB-62, E-MTAB-37, E-GEOD-7307, E-MEXP-2034, E-GEOD-3868, ... (6 experiments)
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1007
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-62
cervical carcinoma
2
E-MTAB-37, E-GEOD-5823
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
198 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-5542, E-GEOD-1417, E-TABM-782, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
glutamine
2
E-MEXP-941, E-MEXP-1335
Infergen + interferon-gamma
1
E-GEOD-5542
unknown
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
trans-hydroxytamoxifen
1
E-GEOD-4025
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-994, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (7 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 98 240
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.315 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM